A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris

Journal of Drugs in Dermatology

Volumn 12, Issue 6, 2013, Pages 633-637

  Alora Palli, Ma Beatrice ^a   Reyes Habito, Claire Marie ^a   Lima, Xinaida T ^b   Kimball, Alexandra B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; PLACEBO;

ACNE VULGARIS; ADULT; ANEMIA; ARTICLE; ATTENTION DEFICIT DISORDER; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INFLAMMATION; LOSS OF APPETITE; MONONUCLEOSIS; MOOD; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STRESS FRACTURE;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; FEMALE; HUMANS; INFLAMMATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TORSO; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878668179     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Tan, JKL, Ediriweera C. Efficacy and safety of combined ethinyl estradiol/drosperinone oral contraceptives in the treatment of acne. International Journal of Women's Health 2009:1 213-221.
2. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007; 56(4):651-63. (Pubitemid 46400177)
3. Redmond G, Olson W, Lippman J, Kafrissen M, Jones T, Jorizzo J. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial. Obstet Gynecol. 1997;89(4):615-22. (Pubitemid 27133540)
4. Lucky A, Henderson T, Olson W, Robisch D, Lebwohl M, Swinyer L. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37(5):746-54. (Pubitemid 27500319)
5. Maloney M, Marbit DI, Flack M, McLaughlin-Miley C, Sevilla C, Derman R. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Women's Health. 2001(2):123.
6. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2007; (1)(1):CD004425.
7. Yaz® (package insert). Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2001.
8. Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P. Treatment of acne using a 3 milligram Drosperinone/20 microgram Ethinyl Estradiol oral contraceptive administered in a 24/4 regimen. The American College of Obstetrics and Gynecologists. 2008; 112(4):773-781.
9. Koltun W, Maloney JM, Marr J and Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20μg plus drosperinone 3 mg administered in a 24/4 regimen: a pooled analysis. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2011; 155:171-175.
10. Tan JK, Tang J, Fung K, Gupta AK, Thomas DR, Sapra S, Lynde C, Poulin Y, Gulliver W and Sebaldt RJ. Development and validation of a comprehensive acne severity scale. J Cut Med and Surg. 2007 (11):1-6.
11. Lello S, Pacifico V, Primavera G, Guardianelli F, Sorge R, Paoletti AM, Melis GB, Raskovic D, Colonna L. Short-term effect of an estroprogestin containing ethinylestradiol 20 mcg +drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism. Minerva Ginecol. 2010 Dec;62(6):509-13.
12. L. Colonna, V. Pacifico, S. Lello, R. Sorge, D. Raskovic, G. Primavera. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venereol. 2011 Oct 19. doi: 10.1111/j.1468-3083.2011.04292.x. [Epub ahead of print]
13. Fruzzetti F. Beyaz®: an oral contraceptive fortified with folate. Womens Health (Lond Engl). 2012 Jan;8(1):13-9.
14. FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. April 10, 2012 Available at http://www.fda.gov/Drugs/DrugSafety/ucm299305.htm. Accessed June 6, 2012.